Double Bond Pharmaceutical AB
1 clinical trials · Sponsor
◉ Watch Double Bond Pharmaceutical AB
| Record | Firm | Date |
|---|---|---|
| A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM (NCT04967690) | Double Bond Pharmaceutical AB | 2024-01-01 |
Track Double Bond Pharmaceutical AB automatically
Every clearance here is in the API, with alerts when new ones post.